Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis*
- 1 December 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 35 (12), 2686-2692
- https://doi.org/10.1097/01.ccm.0000295312.13466.1c
Abstract
To systematically review the literature to assess whether adjunctive therapy with polyclonal intravenous immunoglobulin (ivIg) reduces mortality among critically ill adults with severe sepsis and septic shock. MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases; the meta-register of controlled trials; and the Medical Editors Trial Amnesty register. Prospective randomized clinical trials (RCTs) evaluating ivIg treatment in critically ill adults with severe sepsis or septic shock were included. Two reviewers conducted assessment of suitability for inclusion. Two authors independently determined the validity of included studies and extracted data. The effect of ivIg on all-cause mortality was quantified using a fixed-effect meta-analysis. Fourteen RCTs published between 1988 and 2006 were included. Most were small, used relatively low doses of ivIg, and included predominantly surgical patients with Gram-negative infections. There was a significant reduction in mortality associated with use of ivIg treatment with a pooled odds ratio of 0.66 (95% confidence interval 0.53–0.83;p< .0005). In general, a greater treatment effect was seen among studies of lower methodological quality, studies using higher doses of ivIg, and studies that did not use albumin as a control. There was evidence of between-study heterogeneity (chi-squarep= .009), and this was at least moderate as measured by theI2 value (I2 = 53.8%). When only high-quality studies were pooled, the odds ratio for mortality was 0.96 (95% confidence interval 0.71–1.3;p= .78). This meta-analysis demonstrates an overall reduction in mortality with the use of ivIg for the adjunctive treatment of severe sepsis and septic shock in adults, although significant heterogeneity exists among the included trials and this result was not confirmed when only high-quality studies were analyzed. These data warrant a well-designed, adequately powered, and transparently reported clinical trial.Keywords
This publication has 48 references indexed in Scilit:
- IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*Critical Care Medicine, 2006
- PlaceboThe Lancet, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 2002
- Meta‐analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects modelsStatistics in Medicine, 2001
- High-Dose Intravenous IgG for Treatment of Severe Surgical InfectionsDigestive Surgery, 1996
- Intravenous immunoglobulins in association with antibioticsCritical Care Medicine, 1988
- Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitisKlinische Wochenschrift, 1987
- Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-StationKlinische Wochenschrift, 1986
- Pepsin‐Treated Human Gamma Globulin in Bacterial Infections: A Randomized Study in Patients with Septicaemia and PneumoniaVox Sanguinis, 1981